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Abstract The gekoTM device is a single-use, battery-
powered, neuromuscular electrostimulation device that
aims to reduce the risk of venous thromboembolism
(VTE). The National Institute for Health and Care
Excellence (NICE) selected the gekoTM device for eval-
uation, and invited the manufacturer, Firstkind Ltd, to
submit clinical and economic evidence. King’s Technol-
ogy Evaluation Centre, an External Assessment Centre
(EAC) commissioned by the NICE, independently asses-
sed the evidence submitted. The sponsor submitted evi-
dence related to the gekoTM device and, in addition,
included studies of other related devices as further clinical
evidence to support a link between increased blood flow
and VTE prophylaxis. The EAC assessed this evidence,
conducted its own systematic review and concluded that
there is currently limited direct evidence that gekoTM
prevents VTE. The sponsor’s cost model is based on the
assumption that patients with an underlying VTE risk and
subsequently treated with gekoTM will experience a
reduction in their baseline risk. The EAC assessed this
cost model but questioned the validity of some model
assumptions. Using the EACs revised cost model, the cost
savings for gekoTM prophylaxis against a ‘no prophylaxis’
strategy were estimated as £197 per patient. Following a
second public consultation, taking into account a change
in the original draft recommendations, the NICE medical
technologies guidance MTG19 was issued in June 2014.
This recommended the adoption of the gekoTM for use in
people with a high risk of VTE and when other
mechanical/pharmacological methods of prophylaxis are
impractical or contraindicated in selected patients within
the National Health Service in England.
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Key Points for Decision Makers
The gekoTM device is a small neuromuscular
electrostimulation device that may reduce the risk of
venous thromboembolism (VTE).
The National Institute for Health and Care
Excellence Medical Technologies Evaluation
Programme assessed the gekoTM device for use in
people for whom other methods of prophylaxis are
impractical or contraindicated and who have a high
risk of VTE.
The estimated cost savings for the gekoTM device in
patients at high risk of VTE compared with no
prophylaxis was £197 per patient.
In June 2014, the gekoTM device was recommended
for adoption within the NHS for people who have a
high risk of VTE and for whom other mechanical
and pharmacological methods of prophylaxis are
impractical or contraindicated.
1 Introduction
The role of the National Institute for Health and Care
Excellence (NICE) is to provide guidance and advice to
improve health and social care within the National Health
Service (NHS) in England [1]. Part of this role involves
selecting and evaluating new or innovative medical tech-
nologies for potential adoption within the NHS in England.
The NICE Medical Technologies Evaluation Programme
(MTEP) undertakes this evaluation. The MTEP requires
that for technologies to be eligible for evaluation they must
be suitable for NICE guidance, be a new or innovative
technology and have a current CE (Conformite´ Europe´-
enne) mark or equivalent regulatory approval, or be
expecting one within 12 months [2].
The Medical Technologies Advisory Committee
(MTAC) selects new or innovative technologies for eval-
uation which they consider to have the potential to provide
significant benefits to patients and/or the NHS compared
with current practice. Technologies must be likely to have
the potential either to provide additional benefit to patients
at the same or lower cost to the NHS, or to provide
equivalent benefit to patients at lower cost to the NHS. All
selected technologies proceed through a prescribed evalu-
ation process, which has a timeline of approximately
38 weeks [3]. The MTEP produces a scope outlining the
technology, the intended population and expected out-
comes. The manufacturer then submits clinical and
economic evidence, which meets the NICE scope. An
NICE-funded External Assessment Centre (EAC) assesses
this evidence independently. The EAC will produce a
report based on this evidence and any additional evidence
that was not part of the original manufacturer’s submission,
which may involve additional review/meta-analyses and/or
economic modelling. Input from both public submissions
and independent expert advisors, alongside the submitted
evidence and the EAC’s report, are all considered by the
MTAC at the end of the evaluation process before issuing
guidance for the technology.
The gekoTM device, manufactured by Firstkind Ltd, is a
neuromuscular electrostimulation (NMES) device that is
intended to reduce the risk of venous thromboembolism
(VTE). In June 2014, the NICE issued a final guidance
(MTG19) on this technology [4]. This article presents a
summary of the EAC report and the contribution towards
the NICE guidance for the gekoTM device. It is among a
series of NICE medical technology guidance summaries




VTE is a collective term for both deep vein thrombosis
(DVT) and pulmonary embolism (PE), and is a clinical
condition in which a thrombus (blood clot) forms in a vein
and travels in the blood [10, 11]. In England, it is estimated
that 25,000 people die from hospital-acquired VTE every
year [12].
DVT occurs when a thrombus forms in the deep veins,
usually in the legs, and is the most common form of VTE.
The majority of DVT-related deaths are a result of PE, and
the Office for National Statistics for England and Wales
reports that DVT (International Classification of Diseases,
Tenth Revision [ICD-10] I80.1–I80.3, I80.0 and I82.9) was
the underlying cause of death for 3,798 individuals in 2010
[13].
A PE is a potentially fatal cardiovascular event, which
occurs when a thrombus dislodges from its original site in
the vein, travels in the blood, and subsequently blocks
blood flow in the pulmonary artery. It is suspected that
many PEs are undiagnosed due to diagnostic difficulties
[14]; however, PE remains one of the most common causes
of inpatient deaths in the UK, estimated to be between 2
and 10 % of inpatient deaths annually in the UK [12, 14].
The clinical symptoms of VTE vary significantly and in
some cases it can be asymptomatic. The clinical presen-
tation of VTE may consist of any of the following: leg
swelling/pain, muscle tenderness or cyanosis. More
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specific PE symptoms include dyspnoea, chest pain, fever,
haemoptysis or syncope [15, 16]. A common complication
of DVT is post-thrombotic syndrome (PTS), which is
estimated to occur in more than one-third of all patients
diagnosed with DVT [17]. Symptoms of PTS include
recurrent pain/swelling in the legs, skin changes and
recurrent leg ulcers [10, 18].
The causes of VTE are not clearly understood, but three
clinical features are generally thought to be relevant:
venous stasis, hypercoagulability, and endothelial damage/
dysfunction. These three components represent Virchow’s
triad—a categorised representation of the clinical factors
that predispose to thrombosis [19]. Risk factors for VTE
are considered to be a combination of both patient-related
and setting-related predisposing factors [20]. Patient-rela-
ted risks include, but are not limited to, age, hormonal
therapy, dehydration, active cancer, obesity, one or more
significant medical comorbidities, varicose veins, superfi-
cial VTE, and known thrombophilias [20, 21]. Recent
surgery, hospitalization, recent trauma and immobilization
are considered setting-related risk factors for VTE [20, 21].
Furthermore, DVT, or previous DVT, or PE have been
shown to increase the risk for future VTE [10].
2.2 Risk Assessment and Current Treatment Options
The NICE clinical guideline 92 (CG92) outlines the clini-
cal management of VTE in all patients admitted to hospital
in the UK [10]. This guideline recommends that all patients
admitted to UK hospitals are assessed for VTE risk within
24 h of admission and in the event of any clinical changes
[22, 23]. NICE Pathways outlines a diagnostic tool for
estimating the probability of VTE in primary, secondary
and tertiary care [24]. This clinical prediction tool uses an
adapted two-level DVT/PE Wells score to produce a risk
score for DVT or PE [24, 25] (Appendix 1). A patient with
a high score is regarded as being at-risk for VTE, and the
NICE recommends, where appropriate, the introduction of
suitable prophylaxis. Other methods used for diagnosing
VTE include tests to detect thrombus, i.e. D-dimer assay,
ultrasound or venography, ventilation-perfusion (V/Q)
scan, multidetector helical computed tomography (CT) and
pulmonary angiography [26, 27].
The current standard VTE prophylaxis for patients
includes both pharmacological and/or mechanical methods.
To determine the most appropriate prophylaxis, several
patient-related factors must be considered: the reason for
hospitalisation, medical history, expected treatment from
the intervention, possible harm of prophylaxis and patient
preference. Pharmacological prophylaxis can consist of the
following: low-molecular-weight heparin (or unfraction-
ated heparin [UFH] for patients with severe renal impair-
ment or established renal failure), and fondaparinux [23]. If
a patient is considered to have a risk of bleeding, and this
risk outweighs the risk of VTE, pharmacological prophy-
laxis will not be offered [23]. Mechanical methods include
anti-embolism stockings (thigh- or knee-length), intermit-
tent pneumatic compression (IPC) [thigh- or knee-length]
or foot impulse devices (FID) [23]. CG92 recommends that
all surgical patients receive both forms of prophylaxis (if
pharmacological prophylaxis is not contraindicated) and
that all general medical patients are only given mechanical
VTE prophylaxis if pharmacological prophylaxis is
contraindicated.
If VTE is confirmed via diagnostic tests or suspected
based on the Wells score, there are several treatment
options possible [28]. Anticoagulation medication (such as
heparin or warfarin) may be prescribed to prevent blood
clots getting bigger. Compression stockings can be used to
prevent and/or reduce leg pain/swelling and also reduce the
chance of developing PTS. Patients may also be advised to
elevate their leg to help relieve pressure in the veins of the
calf. In the event that a patient develops a PE, along with
the use of anticoagulation medication, surgery may be
required to remove the thrombus directly.
2.3 The gekoTM Device
The gekoTM device is a single-use, non-invasive NMES
device that is intended to reduce the risk of VTE, and is
manufactured by Firstkind Ltd, a wholly owned subsidiary
of Sky Medical Technology Ltd, UK [29]. In October
2010, the device received a CE mark as a Class IIa medical
device, to increase blood circulation and for the prevention
of venous thrombosis. It is currently available for use in
Europe, Australia, New Zealand and Canada. This CE
mark was extended in 2013 to include preventing and
treating oedema, promoting wound healing and treating
venous insufficiency and ischaemia.
The gekoTM device is a small (149 mm 9
42 mm 9 11 mm), lightweight (18 g), self-adhesive, dis-
posable device that is powered by a non-replaceable, lith-
ium battery [30, 31] (see Fig. 1). It is only available in the
one size, and does not restrict movement of the knee. It has
Fig. 1 The gekoTM device [32]
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seven stimulation modes with selectable pulse widths of
70, 100, 140, 200, 280, 400 and 560 ls (± 5 % ? 20 ls)
[29]. The repetition rate is 1 Hz (± 5 %), with a maximum
charge of 20 lC per pulse. The device is intended to be
used for up to 24 h (maximum of 30 h) before being
replaced. It has a shelf-life of 2 years.
The primary device fitting location positions the head of
the device to the side of the knee over the top of the fibula,
with the tail wrapping to the rear of the leg below the
crease of the knee [33] (see Fig. 2). Alternative fitting
locations align the head of the device with the outer tendon,
either below the crease of the knee or above the crease of
the knee. It is possible to have a device placed on one leg or
on both legs simultaneously. The device aims to imitate the
effect normally achieved by walking by emitting an elec-
trical impulse which stimulates the common peroneal nerve
[31]. This in turn leads to contraction of the calf muscle,
aiding the emptying of veins in the lower limb(s) and
increasing blood circulation to the heart.
2.4 National Institute for Health and Care Excellence
(NICE) Scope
The final scope for the gekoTM for VTE prophylaxis was
developed by the NICE in consultation with relevant
bodies, and published on 21 June 2013 [31]. The scope
defined the patient population as: ‘‘People at risk of VTE
and for whom current mechanical methods of prophylaxis
are impractical or contraindicated. The device is most
likely to be initiated in a hospital inpatient setting’’. The
standard prophylaxis for VTE consists of mechanical and/
or pharmacological methods (as described in detail earlier),
and the scope defined the comparator for this evaluation as
‘no mechanical prophylaxis’. The outcome measures
specified for consideration were venous transit time, blood
flow/velocity, incidence of PTS, DVT, PE and/or VTE,
patient adherence, length of hospital stay and device-rela-
ted adverse events.
The scope requested that the cost analysis use ‘no
mechanical prophylaxis’ as the comparator, and required a
sufficient time horizon and sensitivity analysis to be
undertaken in order to address any uncertainties in the
model parameters. Two specific subgroups were to be
considered: (1) those in whom pharmacological prophy-
laxis is contraindicated; and (2) those in whom pharma-
cological prophylaxis is indicated and prescribed. Patients
with ‘‘fragile skin (for example, older patients and chil-
dren) and those with burns and skin conditions within the
application area of the device’’ and ‘‘patients whose com-
mon peroneal nerve or device application is inaccessible or
where the common peroneal nerve function is impaired’’
were specified in the scope as requiring special
consideration.
3 External Assessment Centre (EAC) Review
The manufacturer’s submission consisted of two sections:
clinical evidence and economic evidence. The clinical
section consisted of an overview and systematic review of
clinical evidence related to the gekoTM device and related
devices (NMES, muscular electrostimulation [MEST],
IPC and FID). The economic evidence provided by the
sponsor consisted of a decision-tree cost model in the
absence of direct economic evidence for the gekoTM
device.
The NICE commissioned King’s Technology Evaluation
Centre (KiTEC), an EAC based in the King’s Health
Partners Academic Health Science Centre (KHP), to cri-
tique the manufacturer’s submission.
Fig. 2 Location of application
of the gekoTM device [32]. The
primary fitting location is for the
gekoTM device to be positioned
over the top of the fibula.
Alternative fitting locations are
aligned with the outer tendon,
below or above the crease of the
knee
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3.1 Clinical Effectiveness Evidence
The sponsor provided a search strategy that was divided
into three sections. The first search strategy related spe-
cifically to studies that used the gekoTM device. The second
and third search strategies related to data on non-pharma-
cological comparators (NMES and IPC). The sponsor sta-
ted that the studies using NMES and IPC devices were
included ‘‘as evidence on the association between
increased blood flow and a reduction in DVT’’. The EAC
considered that all three search strategies should be
regarded as clinical evidence.
The sponsor’s search identified 31 published papers, of
which 21 were considered relevant by the sponsor. Of these
21 papers, one related to gekoTM (non-randomised con-
trolled trial [non-RCT]), 13 related to NMES (seven RCT,
six non-RCT), and seven related to IPC (five RCT, two
non-RCT). The sponsor conducted a search for unpub-
lished studies and within their own database, and identified
a further six studies. Three of the identified studies were
based on a PhD thesis [34]. A search for unpublished
studies related to NMES and IPC was not conducted by the
sponsor (see Appendix 2 for a list of the included studies).
All gekoTM studies reported by the sponsor were
descriptive, were within single centres in the UK and were
conducted on healthy volunteers aged between 18 and
65 years. The application period of the gekoTM device
varied by study, and the use of comparators also varied
substantially; for example, several studies compared the
use of gekoTM with IPC, one compared the gekoTM device
with baseline measures in addition to voluntary dorsiflex-
ions, and one study compared gekoTM in subjects with and
without a plaster cast and in different positions.
The NMES studies identified by the sponsor also varied
in design, from single-centre to multicentre studies, RCT
and non-RCT, and blinded and non-blinded. They are a
combination of studies conducted among healthy volun-
teers (six studies) and medical/surgical patients (nine
studies). The evidence related to IPC consisted of five
RCTs and two observational prospective studies, all of
which were conducted among surgical patients.
3.1.1 Critique of Clinical Effectiveness Evidence
The EAC considered that the sponsor had submitted all of
the available evidence related to the gekoTM device,
including internal post-market surveillance and an interim
report. Seven studies related directly to the use of the
gekoTM device. Of these, all were descriptive studies; there
was a combination of published and unpublished manu-
scripts, and all studies recruited only healthy volunteers.
Three of these studies were considered by the EAC as
providing a suitable comparator, as defined in the final
scope (no mechanical prophylaxis) [35]. These studies
provided clinical evidence that the gekoTM device
increased blood flow in healthy volunteers.
Four of the gekoTM studies identified by the sponsor
were rejected using the EAC search criteria. The study by
Tucker et al. [38] was rejected as the comparator measures
were not controlled adequately and voluntary muscle
action (dorsiflexions), neither of which are listed compar-
ators in the scope. In the study by Warwick et al. [64], the
EAC considered that the lack of a control appropriate to the
scope, as well as the use of cardiac outcomes in the study
by Jawad [39], meant that these studies fell outside the
prescribed scope. The study by Williams et al. [40] did not
provide sufficient detail of how baseline measurements
were obtained, and therefore the EAC could not determine
whether this baseline measurement was suitable as a
comparator, as defined in the scope.
The application period of the gekoTM device varied
substantially between studies, ranging from 15 min to 4 h.
Current management of VTE risk according to the NICE
CG92 recommends the use of prophylaxis continually
‘‘until the risk of VTE recedes with recovery and mobili-
zation, generally 5 to 7 days’’. Therefore, the EAC ques-
tioned the appropriateness of the gekoTM-related studies
submitted by the sponsor, given that none assessed the
device over a time period similar to that used in the rele-
vant clinical setting.
Seven outcomes are listed in the scope; however, only
one of these outcomes (venous transit time, blood flow
and blood velocity) is considered in the gekoTM studies
included by the sponsor as clinical evidence. The EAC
concluded that there are two reasons for this. First, there
is currently limited clinical evidence regarding the
gekoTM device, therefore the sponsor included NMES/
MEST and IPC studies to support a link between
increased blood flow and VTE prophylaxis. Second, the
sponsor failed to include certain outcome terms in the
systematic review. To address this, the EAC conducted a
revised systematic review with additional search terms
related to outcomes, as defined in the scope. The sponsor
excluded studies that used a pharmacological intervention,
which the EAC considered inappropriate given that
patients receiving pharmacological prophylaxis are listed
as a subgroup in the scope. Therefore, the EAC included
this subgroup in its systematic review and also reinstated
the two exclusions listed in the sponsor’s search strategy.
Whilst the EAC identified additional relevant NMES/
MEST and IPC studies (n = 5 additional studies [41–
45]), they did not add to or alter the EAC’s opinion that
there is currently little direct clinical evidence that
gekoTM prevents VTE, and that such evidence as there is
depends on an unproven assumption that blood-flow
measurements predict VTE risk.
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All gekoTM studies included only healthy volunteers,
and may therefore not be generalizable to a typical patient
population. These studies used exclusion criteria and/or
performed prior screening of their subjects to exclude any
subjects presenting with a known risk factor for VTE. The
EAC judged that the population defined in the scope would
include subjects with conditions that may impair the
effectiveness of gekoTM (e.g. oedema, chemical or physical
muscle paralysis, venous insufficiency and adipose tissue
insulating the stimulation area). These factors were effec-
tively ruled out by the exclusion criteria used in the
sponsor-submitted evidence. Therefore, the EAC consid-
ered the population used in the evidence to differ from the
population defined in the scope in ways that might have a
bearing on effectiveness. Outcome measurements varied
substantially between the gekoTM studies, therefore no
meta-analysis or synthesis could be conducted by the
sponsor or the EAC.
The sponsor also provided several studies using NMES
and IPC devices, several of which included a suitable
comparator, as defined in the scope. Only two NMES
studies directly investigated the incidence of DVT along-
side measures of blood flow—Nicolaides et al. [46] and
Velmahos et al. [47]—as well as four of the NMES studies
[45, 48–50], which used an older style of NMES device
that could only be used while patients were under general
anaesthesia. Of the IPC studies, most compared IPC or FID
with a pharmacological intervention. The EAC did not
consider these to be relevant to the scope, and therefore
subsequently excluded these studies.
Overall, none of the gekoTM, NMES and IPC studies
included by the sponsor analysed any potential statistical
association between changes in blood flow and/or velocity
in relation to incidence of DVT or PE/VTE. No reported
studies assessed the outcomes of PTS or length of hospital
stay, as listed in the scope. There are important differences
in both the method of application and the type of electrical
stimulation used by the various gekoTM, MEST and NMES
devices used in the studies.
3.2 Economic Evidence
The manufacturer submitted details of the search strategy
designed to retrieve relevant health economic studies from
published and unpublished literature. The conclusion was
that no economic evidence was available for gekoTM or
other NMES/MEST devices. Therefore, the manufacturer
submitted a decision-tree cost model from the NHS and
personal social services perspective using prices from
2012. The decision-tree structure is an amended version of
that used in the NICE VTE guidelines [10]. The cost model
assessed the impact of gekoTM in the patient population for
whom current mechanical methods of prophylaxis are
impractical or contraindicated. The comparator, as per the
scope, was no mechanical prophylaxis, and the subgroup
analysis related to the use of pharmaceutical prophylaxis
(i.e. combined prophylaxis) and to stroke patients.
The model, as well as all subsequent estimated cost
impacts relating to gekoTM, was built on the assumption
that patients who have an underlying risk of DVT, and who
are subsequently administered the gekoTM device, will
experience a reduction in their baseline risk of DVT. The
model then assumed that a proportion of those patients who
experienced DVT would progress to PE, while the
remainder would have either asymptomatic or symptomatic
DVT.
Subsequently, a proportion of patients were also
assumed to experience PTS, a permanent comorbidity that
can generate costs over the patient’s lifetime. Furthermore,
it was also assumed that the PE patients have a risk of
death. The time horizon for the decision tree was 1 year,
within which time most of the costs associated with pro-
phylaxis, DVT and PE treatment were assumed to occur.
The model included the lifetime (15 years) cost of PTS.
Most of the clinical parameters (Appendix 3) used in the
model were based on the NICE VTE guideline [10] and
other published literature [49]. The important data sources
for costs included the annual Personal Social Services
Research Unit (PSSRU) unit cost compendium [51], NHS
reference costs [52] and other literature [53].
The manufacturer estimated the cost per patient within
the decision model for gekoTM to be £359, and that of the
comparator (no prophylaxis) to be £565, resulting in a cost
saving for gekoTM of £206 per patient. Univariate and
probabilistic sensitivity analysis also showed that gekoTM
is cost-saving compared with no prophylaxis. In the sub-
group analysis, compared with pharmacological prophy-
laxis alone, gekoTM in combination with pharmacological
prophylaxis was not estimated to be a cost-saving option,
with an incremental cost of £69.
3.2.1 Critique of Economic Evidence
The EAC reviewed the search strategy and considered it
appropriate. The EAC additionally searched the NHS
Economic Evaluation Database (EED), which was not
included by the manufacturer. The EAC found no further
useful publications, substantiating the conclusions reached
by the sponsor that no economic evidence is available for
gekoTM or other NMES/MEST devices.
The EAC considered that most of the base-case clinical
parameters and cost estimates used were appropriate and,
wherever there was uncertainty, appropriate sensitivity
analysis was used. The cost model was credible since it was
an amended version of a model that has been used to
develop existing NICE guidelines. The major difference
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between the NICE VTE model and the sponsor’s model is
that the NICE considered DVT and PE as separate arms in
the model, whereas the sponsor modelled PE to commonly
occur as a result of DVT, which the EAC believed was a
reasonable amendment to make. The EAC did not find any
areas for improvement and considered the model structure,
with its assumptions, pathways and health states, to be
sound.
The EAC did not agree with the sponsor’s choice of
the relative risk of 0.39 for DVT with the gekoTM device,
as used in the base-case analysis. This estimated relative
risk was based on the incidence of DVT following use of
NMES, as reported in the literature [49]. The manufac-
turer justified the use of this relative risk value with
reference to the fact that it falls within the range
(0.31–0.58) identified for IPC devices in the NICE VTE
guidelines [10]. The EAC believed that this was a weak
assumption to make in the absence of clinical evidence
that directly links the use of gekoTM with a reduction in
the risk of DVT. The manufacturer had used clinical
evidence to infer that if gekoTM improves venous flow by
the same amount as IPC, it can be assumed to have the
same efficacy as IPC in preventing VTE. The EAC con-
sidered this assumption to be unsubstantiated since, while
IPC devices have been shown clinically to reduce the
incidence of VTE, this prophylactic effect may relate to
any combination of the three components of Virchow’s
Triad, not just increased venous blood flow [54]. Two of
the nominated experts expressed the opinion that venous
volume and venous distension factors may play important
roles. It is not known which of these effects, or combi-
nation of effects, has the greatest impact on VTE pro-
phylaxis [54, 55].
Furthermore, the relative risk pertaining to NMES/
MEST devices may not apply to the gekoTM device since
the devices produce very different types of muscle con-
tractions. Responses from NICE experts on this point were
mixed, although most of them indicated that it was not
appropriate to use the NMES/MEST evidence, especially
from old studies in which the electrical stimuli used were
strong, painful and need to be used under general
anaesthesia.
For the costing, the manufacturer estimated the admin-
istration time for gekoTM by a nurse to be around 1.5 min
per day. The cost per administration of £1.02 in the man-
ufacturer’s model was based on an hourly cost of £41 for a
ward nurse [51]. However, the EAC considered that since
this was a patient contact task, an hourly cost of £100 [51]
should have been used, and this would give a cost per
administration of £2.50. The EAC used this cost to re-
estimate the cost savings of gekoTM in the base-case ana-
lysis. Based on this change, the total cost per patient for
gekoTM prophylaxis was £368 (instead of £359), against
£565 for the ‘no prophylaxis’ strategy. This changed the
cost savings of gekoTM from £206 to £197 per patient.
3.3 Conclusions of the EAC
The sponsor submitted all clinical evidence related to the
gekoTM device. The sponsor’s evidence relied on the
assumption that efficacy in VTE prophylaxis can be
assessed for gekoTM by comparing its effect on venous
blood-flow volume with that of IPC devices. The EAC
considered the outcome of venous blood flow to be a sur-
rogate for prevention of VTE, and noted the conclusions of
a review on the use of surrogate comparisons [56]. This
study demonstrated that, when compared with equivalent
trials that have used true clinical endpoints, surrogates give
over-optimistic results as they are more likely to report
larger treatment effects. Therefore, the EAC was concerned
that this inference may not be sound.
The literature shows that VTE is considered to have
three major risk factors for VTE, known as Virchow’s
Triad. While the EAC agrees that venous stasis is a risk
factor, it does not believe that the literature shows it to be
essential for venous thrombosis [55]. Therefore, the effi-
cacy of VTE prevention is not proven on the basis of
venous stasis prevention alone. The EAC’s consultation
with the nominated experts agreed with this. Therefore, the
EAC considers that it is not sufficient to suggest that the
gekoTM device reduces VTE risk through increasing blood
flow alone. To be confident in VTE risk reduction, evi-
dence is needed to demonstrate that gekoTM can maintain
blood flow at a level that decreases the risk of blood
clotting, taking into account all aspects of Virchow’s Triad.
The sponsor compared the effect of gekoTM on venous
blood flow to that of IPC devices. The inference being
made is that if gekoTM improves venous flow by the same
amount as IPC, it can be assumed that gekoTM is as effi-
cacious as IPC in preventing VTE. The sponsor’s evidence
centres on the assumption that IPC devices work by
increasing venous blood flow, therefore reducing VTE
incidence. However, the EAC questioned the validity of
this given the conflicting evidence for the relationship
between IPC use and VTE prophylaxis. Whilst some
studies documented in this report found a reduction in the
incidence of VTE with the use of IPC, it was not clear
whether this was due to increased venous blood flow or
other prophylactic effects. Furthermore, one of the spon-
sor’s own identified studies found reduced venous blood
flow with IPC use; Jawad [36] documents an average
percentage change to baseline for venous flow of -4 %.
Although the cost-model structure, along with its
assumptions, pathways and health states, is appropriate, the
basic assumption that gekoTM will reduce the relative risk
of DVT is uncertain since there is no direct clinical
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evidence to support this. The EAC believes that there is
now an opportunity to generate new clinical evidence on
the impact of gekoTM on DVT/VTE incidence to populate
an updated economic model.
Overall, it was the EAC’s opinion that there was
insufficient clinical evidence to determine the ability of the
gekoTM device to reduce the risk of VTE. The three main
weaknesses in the evidence provided are that that none of
the studies were performed using patients rather than
healthy volunteers, none were conducted using gekoTM for
an appropriate time period (days instead of hours), and
none used DVT or VTE incidence as the endpoint.
Therefore, the EAC recommended that in order to dem-
onstrate the efficacy of the gekoTM device, it would be
ideal to conduct a carefully designed RCT in patients, with
a suitable comparator or inferiority assessment defined by
the specific measured outcome.
4 NICE Guidance
In accordance with the NICE’s MTEP process, draft rec-
ommendations for the adoption of the gekoTM device were
produced based on deliberation by the MTAC, input from
expert advisors, and the EAC report. Consultation was
conducted among interested parties, and all comments were
collated and submitted to the MTAC after a period of time,
for further discussion.
4.1 Draft Recommendations
In October 2013, the MTAC met and reviewed the spon-
sor’s submission and EAC report together. Input from
expert advisers was also included. Based on this meeting,
the MTAC concluded ‘‘that the gekoTM device showed
promise as a means of VTE prophylaxis’’; however, it
noted the lack of current clinical evidence. Therefore, the
MTAC provisionally recommended further research to
support a case for routine adoption in the NHS [57].
4.2 Consultation Response
Between 13 November and 11 December 2013, public con-
sultation was invited on the published provisional recom-
mendations. During this period, detailed comments (n = 56)
were received, including new evidence provided by the
sponsor. The new evidence consisted of interim results of
two studies using the gekoTM device in patient populations
[58, 59]. The EAC reviewed this new information to deter-
mine whether it added significantly to the evidence provided
in the original submission from the sponsor and the addi-
tional evidence identified by the EAC. The EAC considered
that this new evidence (although interim) was promising as
both studies had been conducted in a patient population with
an activated gekoTM device. The sponsor also provided
additional post-market surveillance data [60], mainly related
to patient wear time of the gekoTM device in a post-surgical
population. However, there were significant limitations in
both the study methodology (in general and in terms of the
scope) and the level of information provided for all three new
pieces of evidence, which casts doubt on the reliability and
interpretation of these interim study results in their present
form. Therefore, the EAC considered that the conclusions
that were presented in the original EAC report remained
valid and appropriate.
The detailed consultation comments challenged several
aspects of the draft guidance. Notably, several expert
advisers who had commented earlier in the evaluation
subsequently submitted comments which re-contextualised
their original advice. Comments sought to clarify areas of
uncertainty around the size of the target unmet need pop-
ulation (n = 14 comments), the use of surrogate outcomes
(such as venous blood flow) in the assessment of VTE
prophylaxis (n = 9 comments), and the magnitude of the
effect of the gekoTM device on VTE with respect to other
mechanical devices (n = 13 comments). The MTEP team,
in collaboration with the EAC, prepared draft responses to
all comments and presented them to the MTAC for con-
sideration at its January 2014 meeting.
During this meeting, the consultation comments were
discussed at length with expert advisers and EAC repre-
sentatives. The subject of the target population and its size
was discussed, as well as the magnitude of the physiolog-
ical effect of the gekoTM device in relation to other
mechanical devices and the mechanism of action versus the
action of exercise. This led the MTAC to change its ori-
ginal provisional research recommendation to one of
positive guidance for the adoption of the gekoTM device in
a limited specific population of patients where the gekoTM
device may reduce the high risk of VTE in patients who
cannot use other forms of prophylaxis.
Due to this change, a second period of public consul-
tation was invited between 19 February and 19 March
2014. During this period, a further seven comments were
received and one additional study abstract was supplied by
the sponsor as clinical evidence. Again, the EAC reviewed
all new information. The comments did not materially
impact on the guidance recommendations and the EAC
considered that the abstract did not add significantly to the
current evidence base, although the study subjects were
patients using the gekoTM device [61].
4.3 Final Guidance
An MTAC meeting was held on 10 April 2014 to produce
final guidance for the gekoTM device for reducing the risk of
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VTE. The MTAC considered the comments arising from the
second consultation and decided not to change the recom-
mendations. The final medical technology guidance
(MTG19) [10] document for the gekoTM device for reducing
the risk of VTE was published by the NICE in June 2014.
The final MTAC guidance for the gekoTM device
included the following recommendations [57]:
1. The case for adopting the gekoTM device is supported
for use in people who have a high risk of VTE and for
whom other mechanical and pharmacological methods
of prophylaxis are impractical or contraindicated.
Although clinical evidence is limited, the case is
supported because of the plausibility that the gekoTM
device may reduce the high risk of VTE in patients
who cannot use other forms of prophylaxis, and the
low risk of the device causing harm.
2. In patients at high risk of VTE who would otherwise
receive no prophylaxis, using the gekoTM device is
estimated to be cost-saving. The amount saved
depends on the level of reduction in relative risk of
DVT associated with gekoTM treatment compared with
no treatment. There is no direct evidence on the size of
this reduction, but when values obtained with other
mechanical methods of prophylaxis were used in cost
modeling, the estimated cost-saving for the gekoTM
device in patients at high risk of VTE compared with
no prophylaxis was £197 per patient.
5 Challenges
The EAC encountered several challenges when reviewing
the clinical evidence for the gekoTM device. One of the
main challenges was the absence of direct clinical evidence
for the efficacy of the gekoTM device. The EAC noted that
the use of blood flow as a surrogate measure of VTE
prevention can lead to over-optimistic results, resulting in
larger treatment effects, and does not account for any
effects on other aspects of Virchow’s Triad. Furthermore,
all of the studies originally submitted as clinical evidence
were conducted among healthy volunteers, measured few
of the outcomes specified in the scope, and assessed the
gekoTM device in such a way as to make comparability
between studies impractical (i.e. it was not possible to
perform meta-analysis). A further challenge was the
inclusion of clinical evidence using NMES/MEST and IPC
studies as these studies were not considered by the EAC to
provide substantial evidence related to the gekoTM device.
A further challenge faced by this and many other
medical technology evaluations was balancing expert
advice against the quality of existing clinical evidence.
Accepted clinical wisdom, which is taken at face value by
expert advisers, may, in reality, lack high-quality and
robust evidence. This was the case with the gekoTM device
and the use of surrogate outcomes, such as venous blood
flow for VTE prophylaxis. A fully powered trial as sug-
gested by several experts would require considerable
numbers; the EAC provided a provisional design for an
RCT to compare gekoTM with a control in patients for
whom no other treatment was possible. The RCT proposed
was a two-arm, randomised controlled superiority trial of
gekoTM versus control in patients in whom no other known
effective treatment was indicated. Using DVT as the pri-
mary outcome, this trial would require 560 patients in total
(n = 280 per arm) using a two-sided design, 5 % signifi-
cance level and 80 % power.
6 Conclusions
The assessment of medical technology is demanding due to
limitations in both the quality and quantity of the evidence-
base available. However, the EAC recognises that it is
important to provide medical options for patients who are
not able to use any other form of device or medication to
reduce DVT risk, and in this context the gekoTM device
may provide a solution.
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Appendix 1: Two-level deep vein thrombosis
and pulmonary embolism Wells score [24]a
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DVT likely C2 PE likely [4
DVT unlikely B1 PE unlikely B4
DVT deep vein thrombosis, PE pulmonary embolism
a NICE Pathways: diagnosing VTE in primary, secondary and ter-
tiary care [24]: adapted with permission from Wells et al. [25, 62]





Tucker et al. [38] gekoTM Contralateral leg
Jawad (cardiac)
[39]




gekoTM No mechanical device
Williams et al. [40] gekoTM Baseline measure and IPC
Jawad et al. (vs.
IPC) [36]
gekoTM Baseline measure and IPC




gekoTM Baseline measure and IPC
Corley et al. [64] NMES No mechanical device
Czyrny et al. [65] NMES IPC
Faghri et al. [66] NMES IPC
Lindstrom et al.
[45]








NMES No mechanical device
Broderick et al.
[67]






NMES No mechanical device in contralateral leg
Griffin et al. [69] NMES No mechanical device at baseline measure
Izumi et al. [70] NMES IPC, electrical muscle stimulation, and
patient’s movements in a variety of
positions
Kaplan et al. [71] NMES No mechanical device in contralateral leg
Nicolaides et al.
[46]









Santori et al. [73] FID Pharmacological prophylaxis
Sobieraj-Teague
et al. [74]
IPC Standard VTE prophylaxis care
Warwick et al. [75] FID Pharmacological prophylaxis
Kurtoglu et al. [76] IPC No mechanical device
Pitto and Young
[77]
IPC Stockings and no mechanical device
FID foot impulse device, IPC intermittent pneumatic compression, NMES neu-
romuscular electrical stimulation, VTE venous thromboembolism
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Appendix 3: Model assumptions for clinical parameters
Assumption Justification
Underlying risk of DVT is
29.1 % with no prophylaxis.
Note: underlying risk of all
other medical patients (23.8 %)
was tested in a sensitivity
analysis
Based on the average risk of
DVT for all surgical-related
patients as per the NICE VTE
clinical guidelines [10]. Risk of
DVT for general medical
patients as per the NICE VTE
clinical guidelines [10]
The proportion of DVT
progressing to a PE is assumed
to be 10.5 %
The NICE VTE clinical
guidelines report the incidence
of symptomatic PE at 3.1 %
[10]. Assuming that PEs occur
as a result of a DVT and the
underlying risk of a DVT is
29.1 %, the proportion of DVTs
that must progress to a PE can
be approximated to 10.5 %
There is a 6 % chance of death
resulting from a PE. No other
mortality is considered
PE fatality rate based on general
surgery patients from the NICE
VTE clinical guidelines [10].
This is considered conservative
as the fatality rate reported is as
high as 44.7 % for the general
medical cohort
RR of a DVT for the gekoTM
device is 0.39
Risk for NMES reported by
Browse and Negus [49]. This
RR is within the ranges
reported for IPC in the NICE
VTE clinical guidelines (0.31
for TKR up to 0.58 for hip-
fracture surgery) and more
conservative than that reported
for NMES by Nicolaides et al.
[78]
PTS occurs in 25 % of patients
with symptomatic DVT, 15 %
of patients with asymptomatic
DVT, and 25 % of patients with
a PE
Based on assumptions made
within the NICE VTE clinical
guidelines [10]
DVT deep vein thrombosis, IPC intermittent pneumatic compression,
NICE National Institute for Health and Care Excellence, NMES
neuromuscular electrical stimulation, PE pulmonary embolism, PTS
post-thrombotic syndrome, VTE venous thromboembolism
Appendix 4: Abbreviations
CE Conformite´ Europe´enne
CG92 NICE clinical guidance 92
CT Computed tomography
DVT Deep vein thrombosis
EAC External assessment centre
FID Foot impulse device
ICD International classification of disease
IPC Intermittent pneumatic compression
KiTEC King’s Technology Evaluation Centre
MEST Muscular electrical stimulation
MTAC Medical Technologies Advisory Committee
MTEP Medical Technologies Evaluation Programme
MTG19 NICE Medical Technology Guidance 19
NHS National Health Service
NHS EED National Health Service Economic
Evaluation Database
NICE National Institute for Health and Care
Excellence
NIHR National Institute for Health Research
NMES Neuromuscular Electrical Stimulation
PE Pulmonary embolism
PSSRU Personal Social Services Research Unit
PTS Post-Thrombotic Syndrome
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